221 related articles for article (PubMed ID: 14712893)
21. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Blinc A; Poredos P
Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
[TBL] [Abstract][Full Text] [Related]
22. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
Faxon DP
Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
[TBL] [Abstract][Full Text] [Related]
23. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
[TBL] [Abstract][Full Text] [Related]
24. [Myocardial infarct, stroke and vascular events reduced by a third].
Z Kardiol; 1997 Nov; 86(11 Suppl Myokardinf):1-3. PubMed ID: 9437253
[No Abstract] [Full Text] [Related]
25. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Rajagopal V; Bhatt DL
Semin Thromb Hemost; 2004 Dec; 30(6):649-55. PubMed ID: 15630671
[TBL] [Abstract][Full Text] [Related]
26. Scientific and therapeutic advances in antiplatelet therapy.
Bhatt DL; Topol EJ
Nat Rev Drug Discov; 2003 Jan; 2(1):15-28. PubMed ID: 12509756
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Hankey GJ
Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelet therapy--Part II.
Goodnight SH; Coull BM; McAnulty JH; Taylor LM
West J Med; 1993 May; 158(5):506-14. PubMed ID: 8342267
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
30. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Milani RV
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S7-S11. PubMed ID: 19213064
[TBL] [Abstract][Full Text] [Related]
31. [Aspirin resistance].
Milicić D; Skorić B
Lijec Vjesn; 2011; 133(9-10):337-42. PubMed ID: 22165084
[TBL] [Abstract][Full Text] [Related]
32. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
Thijs V; Lemmens R; Fieuws S
Eur Heart J; 2008 May; 29(9):1086-92. PubMed ID: 18349026
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet agents and randomized trials.
Diener HC
Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
[TBL] [Abstract][Full Text] [Related]
34. Aspirin resistance in stroke: 2004.
Sztriha LK; Sas K; Vecsei L
J Neurol Sci; 2005 Mar; 229-230():163-9. PubMed ID: 15760636
[TBL] [Abstract][Full Text] [Related]
35. Platelet inhibitors: what are the data in women?
Tempelhof MW; Newby LK
Cardiol Rev; 2008; 16(1):23-9. PubMed ID: 18091399
[TBL] [Abstract][Full Text] [Related]
36. Rationale for the use of antiplatelet drugs in patients with peripheral vascular disease.
Violi F; Balsano F
Clin Trials Metaanal; 1994 Apr; 29(1):81-7. PubMed ID: 10150187
[TBL] [Abstract][Full Text] [Related]
37. Aspirin resistance or variable response or both?
Cheng X; Chen WH; Simon DI
Am J Cardiol; 2006 Nov; 98(10A):11N-17N. PubMed ID: 17097412
[TBL] [Abstract][Full Text] [Related]
38. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
39. Monitoring antiplatelet therapy during peripheral vascular and coronary interventions.
Mahmud E; Ang L
Tech Vasc Interv Radiol; 2006 Jun; 9(2):56-63. PubMed ID: 17482101
[TBL] [Abstract][Full Text] [Related]
40. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
